Diabetes Drugs Ozempic and Mounjaro Shown toโ Significantly Reduce risk of Stroke and โขHeartโ Attack
NEW YORK – Novemberโ 15, 2025 – A landmark study presentedโ today at the American Heart Association’s โฃannual meetingโ reveals โthatโข the diabetes medications Ozempicโข (semaglutide) andโฃ Mounjaro (tirzepatide) offer substantial cardiovascularโ benefits,โข extending โขbeyond blood sugar control to โdemonstrably lower the risk of โstroke and heart attack. The findings,published concurrently in โค The New England Journal of Medicine,represent a potential paradigm shift in the treatment of both โtype 2 diabetes and obesity-related โcardiovascularโค disease.
The research, involving over 10,000 adults with type 2 diabetes and established cardiovascular โdisease, showedโข aโ 14% reduction in the risk of major adverse cardiovascularโค events โ- encompassing stroke, heart attack,โฃ and cardiovascular death – among those treated with Mounjaro comparedโ to placebo. Ozempic demonstrated a similar โฃprotective effect in โa โคseparate, earlierโฃ trial. Theseโค results are notably notable given that individuals with type 2 diabetes face a dramatically increased risk of โคcardiovascular complications, making heart diseaseโ the leading cause of death for this population.
The study’s principal investigator, Dr. Julio Rosenstockโ of โthe University of Alabama at Birmingham, emphasized โtheโ broad implications of theโ data. “We are seeing a level of cardiovascular โขbenefit with these medicationsโ that we haven’t historically observed with other diabetesโ drugs,” โhe โฃstated. “This isn’t just about lowering blood sugar;โ it’s about actively protecting the heart and brain.”
Both Ozempic and Mounjaroโ belong to aโค class of drugs โขknown as GLP-1 receptor agonists, originally developedโ to stimulate insulin โrelease and improve glycemic โcontrol. Though, recent research has highlighted their potentโ effects on weight loss and cardiovascular health. The medications โขwork by mimicking a naturalโ hormone that regulates appetite โคand food intake, leading to significant reductions in body โคweight – an autonomous risk factor for heart disease.
The trials included participants from multiple countries, with an average follow-up โperiod โof three years. Researchers meticulously trackedโค cardiovascular events, analyzing data to determine the magnitude of the protective effects. The findings suggest โthat the benefits extend to a diverse patient โขpopulation, regardless of existing cardiovascular โขtreatments.
Expertsโ anticipate these findings will influence clinical guidelines and treatment โฃstrategies โฃfor individuals with type 2 โฃdiabetes and obesity. The potential for these โฃmedications to prevent life-threatening โcardiovascular events could have โa profound impact on public โhealth,reducing the burden ofโ heart disease and stroke โขglobally. โคFurther research is underway to investigate โคthe long-term effects and optimal useโข of these medicationsโ inโ broader populations.